Law Offices of Frank R. Cruz Encourages Hims & Hers Health, Inc. (HIMS) Investors To Inquire About Securities Fraud Class Action
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Hims & Hers Health, Inc. ('Hims' or the 'Company') (NYSE: HIMS) securities between , inclusive (the 'Class Period'). Hims investors have until August 25, 2025 to file a lead plaintiff motion.
Law Offices of Frank R. Cruz Encourages Hims & Hers Health, Inc. (HIMS) Investors To Inquire About Securities Fraud Class Action
Share
IF YOU SUFFERED A LOSS ON YOUR HIMS & HERS HEALTH, INC. (HIMS) INVESTMENTS, CLICK HERE TO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT.
You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at info@frankcruzlaw.com, by telephone at (310) 914-5007, or visit our website at www.frankcruzlaw.com.
What Happened?
On April 29, 2025, Hims announced a long-term collaboration with Novo Nordisk, starting with the immediate sale of 'a bundled offering of Novo Nordisk's FDA-approved Wegovy on the Hims & Hers platform.'
On June 23, 2025, before the market opened, Novo Nordisk issued a press release announcing that it was terminating its partnership with Hims, 'based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.' The press release stated that Hims 'has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization.'' The press release further stated '[b]ased on Novo Nordisk's investigation, the 'semaglutide' active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers in China' which 'FDA has never authorized or approved' and which may contain 'unsafe and illicit foreign ingredients.'
On this news, the Company's share price fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025, on unusually heavy trading volume.
What Is The Lawsuit About?
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Hims was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk;' (2) that, as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Contact Us To Participate or Learn More:
If you purchased Hims securities, wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please click HERE or contact us at:
Law Offices of Frank R. Cruz
2121 Avenue of the Stars, Suite 800
Telephone: 310-914-5007
Email: info@frankcruzlaw.com
Visit our website at: www.frankcruzlaw.com
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Ellington Financial Announces Estimated Book Value Per Common Share as of May 31, 2025
OLD GREENWICH, Conn., June 26, 2025--(BUSINESS WIRE)--Ellington Financial Inc. (NYSE: EFC) ("we") today announced an estimated book value per share of common stock of $13.41 as of May 31, 2025. This estimate includes the effect of the previously announced monthly dividend of $0.13 per share of common stock, to be paid on June 30, 2025 to holders of record on May 30, 2025, with the same ex-dividend date. Cautionary Statement Regarding Forward-Looking Statements Estimated book value per common share is subject to change upon completion of our month-end and quarter-end valuation procedures relating to our investment positions, and any such change could be material. There can be no assurance that our estimated book value per common share as of May 31, 2025 is indicative of what our results are likely to be for the three- or six- month periods ending June 30, 2025 or in future periods, and we undertake no obligation to update or revise our estimated book value per common share prior to issuance of financial statements for such periods. This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve numerous risks and uncertainties. Our actual results may differ from our beliefs, expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements are not historical in nature and can be identified by words such as "believe," "expect," "anticipate," "estimate," "project," "plan," "continue," "intend," "should," "would," "could," "goal," "objective," "will," "may," "seek" or similar expressions or their negative forms, or by references to strategy, plans, or intentions. Forward-looking statements are based on our beliefs, assumptions and expectations of our future operations, business strategies, performance, financial condition, liquidity and prospects, taking into account information currently available to us. These beliefs, assumptions, and expectations are subject to risks and uncertainties and can change as a result of many possible events or factors, not all of which are known to us. If a change occurs, our business, financial condition, liquidity, results of operations and strategies may vary materially from those expressed or implied in our forward-looking statements. The following factors are examples of those that could cause actual results to vary from our forward-looking statements: changes in interest rates and the market value of our investments, market volatility, changes in mortgage default rates and prepayment rates, our ability to borrow to finance our assets, changes in government regulations affecting our business, our ability to maintain our exclusion from registration under the Investment Company Act of 1940, our ability to maintain our qualification as a real estate investment trust, or "REIT," and other changes in market conditions and economic trends, such as changes to fiscal or monetary policy, heightened inflation, slower growth or recession, and currency fluctuations. Furthermore, forward-looking statements are subject to risks and uncertainties, including, among other things, those described under Item 1A of our Annual Report on Form 10-K, which can be accessed through our website at or at the SEC's website ( Other risks, uncertainties, and factors that could cause actual results to differ materially from those projected or implied may be described from time to time in reports we file with the SEC, including reports on Forms 10-Q, 10-K and 8-K. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. This release and the information contained herein do not constitute an offer of any securities or solicitation of an offer to purchase securities. About Ellington Financial Ellington Financial invests in a diverse array of financial assets, including residential and commercial mortgage loans and mortgage-backed securities, reverse mortgage loans, mortgage servicing rights and related investments, consumer loans, asset-backed securities, collateralized loan obligations, non-mortgage and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments. Ellington Financial is externally managed and advised by Ellington Financial Management LLC, an affiliate of Ellington Management Group, L.L.C. View source version on Contacts Investors:Ellington FinancialInvestor Relations(203) 409-3575info@ orMedia:Amanda Shpiner/Grace CartwrightGasthalter & Ellington Financial(212) 257-4170ellington@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
18 minutes ago
- Business Wire
DNOW Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of DNOW Inc. is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of DNOW Inc. (NYSE: DNOW) and MRC Global Inc. is fair to DNOW shareholders. Upon completion of the proposed transaction, DNOW shareholders will own approximately 56.5% of the combined company on a fully diluted basis. Halper Sadeh encourages DNOW shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@ or zhalper@ The investigation concerns whether DNOW and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for DNOW shareholders; and (2) disclose all material information necessary for DNOW shareholders to adequately assess and value the merger consideration. On behalf of DNOW shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
Business Wire
20 minutes ago
- Business Wire
Hims & Hers Health, Inc. (NYSE: HIMS) Accused of 'Illegal Mass Compounding and Deceptive Marketing' Practices; Investors Urged to Contact Award-Winning Firm, Gibbs Mura
OAKLAND, Calif.--(BUSINESS WIRE)--Gibbs Mura announces that on June 25, 2025, a lawsuit was filed against Hims & Hers Health, Inc. ('Hims and Hers') on behalf of investors who purchased or acquired Hims & Hers securities between April 29, 2025, and June 23, 2025. Shares of Hims & Hers previously fell over 33% in intraday trading on Monday, June 23, 2025, after Novo Nordisk announced it was ending its collaboration with the telehealth company following concerns that it was engaging in 'deceptive promotion and selling of illegitimate, knockoff versions of [weight loss drug] Wegovy that put patient safety at risk.' Gibbs Mura encourages investors to contact us about their legal rights and options in the Hims & Hers Health, Inc. (NYSE: HIMS) Securities Class Action Lawsuit. What Should Hims & Hers Investors Do? If you invested in HIMS, visit our Hims & Hers Health, Inc. lawsuit investigation webpage, or call us at (888) 410-2925 to get more information about how you may be able to recover your losses. Our investigation concerns whether Hims & Hers has violated federal securities laws by providing false or misleading statements to investors. What is the Hims & Hers Lawsuit Investigation About? On June 23, 2025, Novo Nordisk announced it was terminating its collaboration with Hims and Hers following concerns that it was reportedly engaging in deceptive marketing practices and illegally promoting cheaper knock-off versions of the weight loss drug, Wegovy. In April 2025, Novo Nordisk said it would offer Wegovy through a number of telehealth companies, including Hims & Hers, following the end of a Wegovy shortage. The end of this shortage 'meant compounding pharmacies were legally restricted from making and selling cheaper, unapproved versions of the drug by May 22 – with rare exceptions,' as reported by CNBC. Then, on Monday, June 23, 2025, Novo Nordisk issued a statement that it was terminating its relationship with Hims and Hers because the company 'failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization,'' adding that the company is 'disseminating deceptive marketing that put patient safety at risk.' The lawsuit alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and specifically failed to disclose to investors that Hims and Hers was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk' and 'as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated.' About Gibbs Mura, A Law Group Gibbs Mura represents investors nationwide in securities litigation to correct abusive corporate governance practices, breaches of fiduciary duty, and proxy violations. The firm has recovered over a billion dollars for its clients against some of the world's largest corporations, and our attorneys have received numerous honors for their work, including 'Best Lawyers in America,' 'Top Plaintiff Lawyers in California,' 'California Lawyer Attorney of the Year,' 'Class Action Practice Group of the Year,' 'Consumer Protection MVP,' and 'Top Women Lawyers in California.' This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
